Hanmi Pharm. Co., Ltd.
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 128940.KS | 000100.KS | SUNPHARMA.NS | 600276.SS | 1795.TW | AUROPHARMA.NS | |
|---|---|---|---|---|---|---|
| Market cap | 4.82T | 6.47T | 4.19T | 314.47B | 46.89B | 908.41B |
| P/E (TTM) | — | — | 34.6 | 40.8 | 12.4 | 24.7 |
| Forward P/E | — | — | 26.9 | 30.8 | 7.4 | 16.9 |
| Price/book | — | — | 5.0 | 5.1 | 2.0 | 2.4 |
| Dividend yield | 0.53% | 0.70% | 0.92% | 0.38% | 1.47% | — |
| 1-year change | +8.45% | −27.20% | +3.11% | −27.29% | −39.08% | +47.52% |
| Today | +0.26% | +0.46% | +0.12% | −0.15% | +0.57% | −2.63% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 20 min.
Latest news
All 128940.KS news ›Hanmi Pharm prices domestic obesity drug Epe at half the cost of Mounjaro
First month at 129,800 won, maintenance dose at 299,200 won Early-entry and long-term cost relief backed by Pyeongtaek plant supply chain Aggressive pricing set to reshape market dominated by foreign brands South Korea's first homegrown…
Hanmi Pharm's domestic obesity drug 'Epe' could cost a third of rivals
Hanmi Pharm to launch Korea's first homegrown GLP-1 obesity drug as early as this month Market watches whether Epe can break Wegovy-Mounjaro duopoly with a price tag in the 100,000-won range Hanmi Pharm is preparing to challenge the…
Hanmi Pharm's obesity treatment Eppe wins domestic approval
Hanmi Pharm headquarters in Songpa, Seoul / Courtesy of Hanmi Pharm Eppe is the 45th novel drug developed in Korea and the country's first domestically developed GLP-1-based obesity drug. It has been approved in five doses: 2, 4, 6, 8 and…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
mbiz.heraldcorp.com2
-
asiae.co.kr1
-
koreatimes.co.kr1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 4 articles, not a forecast.